AdventRx Showing Signs Of Life With SynthRx Acquisition, NDA For Exelbine
This article was originally published in The Pink Sheet Daily
Executive Summary
Company moving into sickle cell disease in all-stock acquisition of privately held SynthRx.
You may also be interested in...
Mast Therapeutics Changes Its Name In Hopes Of A Fresh Start
Formerly called Adventrx, the company says the name Mast better reflects its current strategy, which includes a focus on a Phase III asset for sickle cell disease. With a new name and a late-stage trial underway, management is hoping to persuade skeptical investors to take a second look.
Troubled Biotechs Revisited: Peregrine Placing All Of Its Chips On Bavituximab
The story doesn’t end once a company is profiled in our periodic “troubled biotechs” roundups – here we check back in on three firms.
Troubled Biotechs: Adventrx, EntreMed, Peregrine, Anesiva
Adventrx enacts second staff reduction to continue operations as top two candidates near FDA filing.